Stock Analysis of Aclaris Therapeutics Inc (ACRS) - Birds Eye View

1W   2W   1M   3M   1Y   2Y   5Y   
Overview
Code ACRS
Close 1.18
Change 0 / 0 %
Volume 404991
Vol Change -225241.00 / 35.74 %
IndustryDiagnostics & Research
SectorHealthcare
AIO Strength Index
Technical StrengthNeutral
Growth Index Low Growth Stock
Value Index Poor Value Stock
Profitability Index Poor Profitability Stock
Stability Index No Significant Stability


Fundamental View of Aclaris Therapeutics Inc
PE (TTM)

-810.90

Very Poor
Price / Book

385.75

Very Poor
Price / Sales

2013.30

Very Poor
Piotroski F Score

4.0

Indecisive
Market Cap

84092.46 K

Enterprise Value

44640.46 K

ROA (TTM)

-36.61

Very Poor
ROE (TTM)

-47.57

Very Poor
Net Margin (TTM)

-248.28

Very Poor
Revenue

5.03 %

31249.00 K
Net Profit

1.81 %

-88481.00 K
Debt to Equity

0.0027

Excellent
Altman Z Score

-5.10

Very Poor
Quick Ratio

0

Poor
Cash Ratio

3.85

Very Good


Highs/Lows of Aclaris Therapeutics Inc
PeriodOld priceStock ReturnS&P 500 ReturnsHighLowHigh DateLow Date
One Week1.225 3.67 % 1.59 % 1.261.1410-May-2413-May-24
Two Week1.31 9.92 % 4.60 % 1.40351.1406-May-2413-May-24
One Month1.22 3.28 % 4.86 % 1.40351.1406-May-2413-May-24
Three Month1.19 0.840 % 5.82 % 1.511.1106-Mar-2415-Mar-24
Six Months0.8852 33.30 % 17.50 % 1.510.7706-Mar-2427-Nov-23
One year8.18 85.57 % 28.89 % 11.120.590217-Jul-2313-Nov-23
Two year11.03 89.30 % 32.16 % 18.9580.590216-Nov-2213-Nov-23
Five year5.76 79.51 % 84.16 % 18.9580.590216-Nov-2213-Nov-23


Technical View of Aclaris Therapeutics Inc
RSI

43.93

Neutral
MACD

-0.0087

Bearish
ADX

13.72

Neutral
Super Trend

1.16

Mild Bullish
Williams %R

-84.82

Mild Bullish
CCI

-82.08

Neutral


EMA 5

1.19

Mild Bearish
EMA 15

1.22

Mild Bearish
EMA 50

1.25

Bearish
EMA 100

1.66

Mild Bearish
SMA 100

1.20

Strong Bearish
SMA 200

3.14

Mild Bearish
SMA 5 / 20

1.18 / 1.23

Bearish
SMA 15 / 50

1.24 / 1.22

Mild Bullish
SMA 50 / 200

1.22 / 3.14

Mild Bearish




Charts of Aclaris Therapeutics Inc


Returns of Aclaris Therapeutics Inc with Peers
Period / StockACRSBDSXGTHBNRSPRO
1 Week-3.67%0.645%0.374%930.15%-7.10%
1 Mth-3.28%24.80%3.21%956.44%6.80%
3 Mth-0.840%5.41%8.78%888.31%2.61%
6mth33.30%9.86%68.66%791.33%35.34%
1 Year-85.57%24.30%34.17%184.75%-12.29%
2 Year-89.30%-7.14%-54.05%154.11%-8.19%
5 Years-79.51%----86.89%
charts-
View All Together in Chart      Inline           Tile

Compare Fundamentals of Aclaris Therapeutics Inc with Peers
Ratio / StockACRSBDSXGTHBNRSPRO
PE-810.90-2.91-0.197-1.30573.75
P/B385.75-142.520.1740.932274.88
ROA-36.61-54.53-57.04-52.6026.98
ROE-47.570-88.89-71.4547.91
Debt To Equity0.00277.760.2530.01120.0161
Revenue31249.00 K
5.03 % 		44026.00 K
15.22 % 		650706 K
22.32 % 		558587 K
0.826 % 		76194.00 K
42.39 %
Net Income-88481.00 K
1.81 % 		-63345.00 K
3.21 % 		-808403.00 K
62.91 % 		-707701.00 K
27.13 % 		-1614.00 K
96.52 %


Technicals of Aclaris Therapeutics Inc with Peers
Technical / StockACRSBDSXGTHBNRSPRO-
ADX13.7222.6537.0224.2222.97
CMF0.01200.593-0.136-0.203-0.312
MFI55.5967.8088.3238.0361.92
RSI43.9364.9170.4495.4547.33
MACD Abv SignalFalseTrueTrueTrueTrue
Price Above 50 MAFalseTrueTrueTrueFalse-
Price Above 200 MAFalseFalseTrueTrueTrue-


About : Aclaris Therapeutics Inc

Address : 701 Lee Road, Wayne, PA, United States, 19087
Tel : 484 324 7933
URL : https://www.aclaristx.com
Code : ACRS, ISIN : US00461U1051, Exchange : NASDAQ, Country : USA
Fiscal Year End : December
IPO date : 07_Oct_2015
Employee Count : 86

Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.


Note : All Data Generated at the End of Trading Hours (EOD Data)